Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy

Research output: Contribution to journalArticle

Abstract

Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors.

In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.
LanguageEnglish
Number of pages30
JournalJournal of Liposome Research
Publication statusAccepted/In press - 22 Apr 2019

Fingerprint

Transferrin
Aspirin
Neoplasms
Pharmaceutical Preparations
Therapeutics
Intravenous Administration
Anti-Inflammatory Agents
Cell Line
In Vitro Techniques

Keywords

  • aspirin
  • transferrin
  • tumor targeting
  • drug delivery
  • cancer therapy

Cite this

@article{964c0b90991f4472876458ad200d9ecb,
title = "Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy",
abstract = "Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors.In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.",
keywords = "aspirin, transferrin, tumor targeting, drug delivery, cancer therapy",
author = "Intouch Sakpakdeejaroen and Sukrut Somani and Margaret Mullin and Christine Duf{\`e}s",
year = "2019",
month = "4",
day = "22",
language = "English",
journal = "Journal of Liposome Research",
issn = "0898-2104",

}

TY - JOUR

T1 - Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy

AU - Sakpakdeejaroen, Intouch

AU - Somani, Sukrut

AU - Mullin, Margaret

AU - Dufès, Christine

PY - 2019/4/22

Y1 - 2019/4/22

N2 - Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors.In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.

AB - Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors.In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.

KW - aspirin

KW - transferrin

KW - tumor targeting

KW - drug delivery

KW - cancer therapy

UR - https://www.tandfonline.com/loi/ilpr20

M3 - Article

JO - Journal of Liposome Research

T2 - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

ER -